BIOVIE Amends S-1/A, Signaling Capital Raise Efforts

TL;DR

**BIOVIE's S-1/A is a clear signal they're gearing up for a capital infusion, so watch for potential dilution but also for funding that could propel their drug pipeline.**

AI Summary

BIOVIE INC. (BIVIW) filed an S-1/A on July 22, 2025, indicating an amendment to its registration statement. The filing covers the period from July 1, 2024, to March 31, 2025, and includes financial data up to December 31, 2024. While specific revenue and net income figures are not explicitly detailed in the provided excerpt, the amendment focuses on capital structure changes, including common stock, additional paid-in capital, and retained earnings. The company, formerly NANOANTIBIOTICS, INC., operates in Pharmaceutical Preparations (SIC 2834). Key financial movements include adjustments to equity accounts across various quarters, such as a change in Additional Paid-In Capital from June 30, 2022, to December 31, 2024. The strategic outlook appears centered on securing capital through this offering, as evidenced by the S-1/A filing, which is a common step for companies seeking to raise funds or register securities for public sale. Risks are implicitly tied to the early-stage nature of a pharmaceutical company and its reliance on successful clinical development and market acceptance.

Why It Matters

This S-1/A filing is crucial for investors as it signals BIOVIE INC.'s intent to potentially raise capital or register securities, which could dilute existing shareholder value but also fund critical drug development. For employees, a successful offering could provide job security and resources for ongoing research in the competitive pharmaceutical sector. Customers, particularly future patients, depend on BIOVIE's ability to fund and advance its pharmaceutical preparations. The broader market will watch how BIOVIE navigates the capital markets, especially given its classification in the highly competitive pharmaceutical industry (SIC 2834), where funding is paramount for innovation and market entry.

Risk Assessment

Risk Level: high — The risk level is high because BIOVIE INC. operates in the pharmaceutical preparations industry (SIC 2834), which is inherently capital-intensive and subject to extensive regulatory hurdles and clinical trial failures. The S-1/A filing itself, while a necessary step for capital raising, indicates the company's need for external funding, suggesting potential financial instability or significant future expenditures without guaranteed returns.

Analyst Insight

Investors should closely monitor the terms of the upcoming offering, including the number of shares to be registered and the expected price, to assess potential dilution. Evaluate BIOVIE's current pipeline and clinical trial progress, as successful drug development is the primary driver of value for pharmaceutical companies.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

0%

total Assets

$0

total Debt

$0

net Income

$0

eps

$0

gross Margin

0%

cash Position

$0

revenue Growth

N/A

Key Numbers

• 2025-07-22 — Filing Date (Date S-1/A was filed by BIOVIE INC.)
• S-1/A — Form Type (Amendment to initial registration statement for public offering)
• 0001580149 — Central Index Key (CIK) (Unique identifier for BIOVIE INC. with the SEC)
• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
• NV — State of Incorporation (BIOVIE INC. is incorporated in Nevada)
• 0630 — Fiscal Year End (BIOVIE INC.'s fiscal year ends on June 30)
• 79 — Public Document Count (Number of public documents associated with this filing)
• 2013-06-25 — Date of Name Change (When NANOANTIBIOTICS, INC. became BIOVIE INC.)

Key Players & Entities

• BIOVIE INC. (company) — Filer of S-1/A
• NANOANTIBIOTICS, INC. (company) — Former name of BIOVIE INC.
• SEC (regulator) — Recipient of S-1/A filing
• 0001580149 (dollar_amount) — Central Index Key (CIK) for BIOVIE INC.
• 333-288525 (dollar_amount) — SEC File Number for the S-1/A
• 680 W NYE LANE, SUITE 201, CARSON CITY, NV 89703 (company) — Business address of BIOVIE INC.
• 775-888-3162 (dollar_amount) — Business phone number of BIOVIE INC.
• 2025-07-22 (dollar_amount) — Filing date of S-1/A
• 2013-06-25 (dollar_amount) — Date of name change from NANOANTIBIOTICS, INC. to BIOVIE INC.
• 2834 (dollar_amount) — Standard Industrial Classification (SIC) code for Pharmaceutical Preparations

FAQ

Industry Context

BIOVIE INC. operates within the Pharmaceutical Preparations sector (SIC 2834). This industry is characterized by high research and development costs, lengthy product development cycles, and stringent regulatory oversight from bodies like the FDA. Companies in this space often rely on innovation and clinical trial success to bring new treatments to market, facing competition from both large established pharmaceutical companies and emerging biotechnology firms.

Regulatory Implications

As a pharmaceutical company, BIOVIE INC. is subject to extensive regulatory scrutiny, particularly concerning the development, testing, and marketing of its products. The S-1/A filing itself is a regulatory requirement for public offerings. Future success will heavily depend on navigating FDA approval processes and adhering to Good Manufacturing Practices (GMP) and other compliance standards.

What Investors Should Do

1. Review the full S-1/A filing for detailed financial statements and management discussion.
2. Analyze the company's capital structure changes and the implications of the current offering.
3. Assess the company's stage of development and clinical pipeline.

Key Dates

• 2013-06-25: Company Name Change — Indicates a rebranding or strategic shift from NANOANTIBIOTICS, INC. to BIOVIE INC., potentially signaling a new phase or focus.
• 2024-07-01: Start of Reporting Period — Marks the beginning of the financial period covered by the S-1/A filing, crucial for understanding the company's recent operational and financial activities.
• 2025-03-31: End of Reporting Period — Defines the end of the financial period for which the S-1/A provides updated information, setting the stage for the current capital raise.
• 2025-07-22: S-1/A Filing Date — The date BIOVIE INC. filed its amended registration statement, signaling its intent to offer securities to the public and providing updated disclosures.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC. It is used to correct or supplement information previously filed on an S-1 form, often in preparation for an initial public offering (IPO) or other public securities offerings. (This filing indicates BIOVIE INC. is updating its disclosures as part of a process to offer securities, likely to raise capital.)

Additional Paid-In Capital

The amount of money a company has received from selling stock above its par or stated value. It represents capital contributed by investors in excess of the nominal value of the shares. (Changes in this account reflect equity transactions, such as stock issuance, which are central to the capital structure adjustments discussed in the S-1/A.)

Retained Earnings

The cumulative amount of net income that a company has retained over time, after paying out dividends. It represents profits reinvested back into the business. (Fluctuations in retained earnings can indicate profitability or losses, and are a key component of a company's equity structure.)

SIC Code 2834

Standard Industrial Classification code for Pharmaceutical Preparations. This industry includes establishments primarily engaged in the manufacturing of pharmaceutical preparations (e.g., medicines, vaccines, vitamins) by compounding and mixing of purchased pharmaceutical ingredients. (Classifies BIOVIE INC. within the pharmaceutical sector, highlighting its business focus and the associated industry dynamics and regulatory environment.)

Year-Over-Year Comparison

This S-1/A filing represents an amendment to a registration statement, indicating a new or updated effort to raise capital or register securities. Specific comparative financial metrics against a prior filing are not detailed in the provided excerpt. However, the focus on capital structure changes, including common stock and additional paid-in capital, suggests ongoing equity transactions. The period covered (July 1, 2024, to March 31, 2025) implies updated financial information is being presented, but direct year-over-year comparisons of revenue, net income, or margins cannot be made without access to prior period financial statements within the filing.

Filing Details

This Form S-1/A (Form S-1/A) was filed with the SEC on July 22, 2025 regarding BIOVIE INC. (BIVIW).

View full filing on EDGAR

View Full Filing

View this S-1/A filing on SEC EDGAR